Unither Pharmaceuticals Offers a Compatibility Study For Injectable Products

Unither will be present at the World Vaccine Congress 2026 in Washington, US, where the company will introduce a new initiative to identify promising collaborations in vaccines and biologics.

Through this action, Unither invites biotech and pharmaceutical companies developing innovative injectable therapies to apply for a free preliminary compatibility study with the Euroject® platform, Unither’s Blow-Fill-Seal (BFS) single-dose injection technology. The selected project will have the opportunity to evaluate the compatibility of its vaccine or biologic candidate with the Euroject® delivery system and explore a potential pilot fill-and-finish evaluation.

Companies attending the congress are encouraged to visit Unither at Booth 522 to learn more about the program and discover the potential of the Euroject® platform.

About Euroject®

Euroject® is an innovative single-dose injection device using BFS technology. This prefilled format enables simple, safe and cost-effective vaccine administration, reducing logistical complexity and supporting large-scale immunisation programmes.

Our dedicated building in Amiens, equipped with five filling lines, can produce over one billion doses per year, making Euroject® a powerful solution for global vaccination needs.

Explore everything on our brand new website section dedicated to: EUROJECT® | BFS Injectable | Prefilled Syringe | Unither 

Looking forward to connecting with you and exploring future collaboration opportunities.